All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The ALL Hub is happy to present a visual abstract representing key data from the final analysis of the RIALTO study, a multicenter expanded access program evaluating the safety and efficacy of blinatumomab in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (B-ALL).
Sequential treatment with blinatumomab and inotuzumab in patients with relapsed B-ALL
In comparison to conventional chemotherapy, both blinatumomab and inotuzumab show superior antileukemic activity and are favored for salvage treatment, including...
Hyper-CVAD with sequential blinatumomab for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative B-cell ALL
Despite high rates of complete remissions, long-term survival in patients with B-cell acute lymphoblastic...
Subscribe to get the best content related to ALL delivered to your inbox